Skye Bioscience shares are trading lower after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve target product profile and has discontinued the program.
Portfolio Pulse from Benzinga Newsdesk
Skye Bioscience shares are trading lower after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve the target product profile and has discontinued the program.
June 10, 2024 | 12:25 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Skye Bioscience shares are trading lower after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve the target product profile and has discontinued the program.
The discontinuation of the SBI-100 Ophthalmic Emulsion Phase 2a trial is a significant setback for Skye Bioscience, leading to a negative market reaction and a drop in share price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100